VistaGen Therapeutics logo
VistaGen Therapeutics VTGN
$ 0.6 -0.9%

Quarterly report 2025-Q4
added 02-12-2026

report update icon

VistaGen Therapeutics Cash Flow 2011-2026 | VTGN

Annual Cash Flow VistaGen Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-42.1 M -25.8 M -49.7 M -45.3 M -12.1 M -15.8 M -14.5 M -9.06 M - - -2.77 M -2.13 M -3.46 M -3.57 M -841 K

Depreciation & Amortization

150 K 127 K 130 K 154 K 118 K 103 K 91.2 K 80.7 K 54.9 K 53.5 K 59.1 K 54.6 K 33.8 K 45.6 K 45.3 K

Accounts Payables

653 K 1.55 M 2.47 M 2.76 M 838 K 1.84 M 1.06 M 1.2 M 867 K 936 K 2.25 M 2.44 M 1.35 M 1.75 M -

Accounts Receivables

- - - - - - - - - - - 2.8 K - 106 K -

All numbers in USD currency

Quarterly Cash Flow VistaGen Therapeutics

2025-Q4 2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -18.8 M - - -10.9 M - - -7.89 M - - -42.2 M -16 M - - -29.7 M -17.6 M - - -6.79 M -1.8 M -2.81 M - -13.2 M -8.9 M -4.76 M - -11 M -7.06 M - - - -2.13 M - - -5.97 M -3.87 M - - -3.5 M -2.33 M - - -1.87 M -1.53 M - - -1.66 M -1.32 M - - -2.49 M -1.53 M - - -2.85 M -1.79 M -

Depreciation & Amortization

- - 40 K - - 34 K - - 32 K - 30.6 K 96.2 K 32.3 K - 43.7 K 115 K 71.2 K - 26.4 K 25.5 K 25.4 K - 25.5 K 77.6 K 52.1 K 26.2 K - 64.8 K 37.9 K - - - 23.6 K - - 37.6 K 26 K - - 40.8 K 28.9 K - - 39.2 K 26.2 K - - 40.2 K 25.8 K - - 21 K 11.8 K - - 33.5 K 21.3 K -

Accounts Payables

1.28 M 1.83 M 486 K 1.04 M 715 K 1.21 M 1.74 M 1.3 M 1.62 M 2.47 M 1.6 M 2.96 M 5.47 M 2.76 M 1.95 M 2.66 M 2.32 M 838 K 776 K 1.18 M 1.31 M 1.84 M 1.61 M 1.45 M 934 K 1.06 M 1.09 M 590 K 630 K 1.2 M 509 K 1.15 M 632 K 867 K 874 K 930 K 930 K 936 K 1.1 M 1.11 M 1.55 M 2.25 M 2.42 M 2.25 M 1.9 M 2.44 M 2.26 M 1.98 M 1.76 M 2.44 M 1.25 M 1.47 M 2.56 M 1.35 M 1.04 M 1.24 M 943 K 1.77 M

Accounts Receivables

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1.25 M - - - - - - - - 2 K 5.3 K 2.8 K 2.8 K 2.8 K 2.8 K - - 1.6 K 1.6 K 106 K 7.78 K 127 K 149 K 42.2 K

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company VistaGen Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.67 -0.07 % $ 6.09 B irlandaIrlanda
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 2.82 1.44 % $ 283 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.29 -3.01 % $ 329 M britainBritain
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 3.47 -1.7 % $ 221 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.74 -12.17 % $ 3.25 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.09 -9.17 % $ 22.4 M israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Equillium Equillium
EQ
$ 2.06 - $ 118 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.85 3.26 % $ 592 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 23.45 -1.64 % $ 631 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 1.32 -5.2 % $ 1.88 M chinaChina
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.55 0.98 % $ 4.28 B schweizSchweiz
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.45 -1.77 % $ 853 M canadaCanada
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA